2023 Analytical Tool on Targeting the CD47-SIRPA Axis in Oncology - Intense Global Interest and a Growing List of Stakeholders Operating in this Field
Saturday, February 11, 2023
DUBLIN, Feb. 3, 2023 /PRNewswire/ -- The "Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response.
This report reveals intense global interest and a growing list of stakeholders operating in this field. Users of this report get an un-biased, fact driven analysis of the position of each molecule and commercial player, always kept up to date with twice weekly updates.
This analytical tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of immune-oncology.
This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your drug surveillance and intelligence of the CD47-SIRPA axis in oncology, allowing you to power your decision making and advance your own interests.
Keeping you "In the know"
Simply put, our mission is to fuel your knowledge of immune-oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool achieves this by continuously scanning development in CD47-SIRPA axis in oncology and reporting:
-- Deals & Collaborations
-- New technologies/drugs (emerging from patents, grants, abstracts (see
Conference Coverage) etc.)
-- Funding/Grants/IPOs
-- Filings & Approvals
-- Latest Clinical Trial Development & Results
-- Newly launched clinical trials
-- Conference Coverage of the world's twelve leading meetings in oncology*
-- Quarterly & Annual Reporting
This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today!
Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:
-- Emerging Technologies
-- Target Novelty
-- Recent Funding
-- Early & Late Stage Pipeline
-- Biomarker/Companion Diagnostic Development (featured below)
-- Entered Deals & Alliances
-- Conference surveillance of world leading cancer meetings (featured
below)
-- Combination Therapy Choices (featured below)
-- Outcome of Clinical Trials
-- Indication Selection & Expansion Choices
-- Drug Repositioning Opportunities
For 20 years the author has supported better decision making across the oncology drug development industry. Your Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computers desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.
Your Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool covers more than 70 companies and partners who are today developing 81 CD47-SIRPA axis targeting drugs where of 76 are in active development in cancer across 28 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.
Let our expertise work for you
With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.
Your key to access development at the world-leading cancer meetings
The Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conferences in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.
Run combination therapy analysis like no other
The Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.
Unparalleled biomarker surveillance
We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.
Support and inspiration at your finger-tips
You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.
A tool to grow with and keep you informed
Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.
System Requirements
-- Browser Application (Supports: Internet Explorer, FireFox, Chrome and
Safari))
-- Internet access
For more information about this report visit https://www.researchandmarkets.com/r/aqy5x9-the?w=5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/2023-analytical-tool-on-targeting-the-cd47-sirpa-axis-in-oncology---intense-global-interest-and-a-growing-list-of-stakeholders-operating-in-this-field-301738471.html
SOURCE Research and Markets
|
|
|
|
|
 |
Energy Toolbase Launches Energy Storage Partnership with Sungrow to Support PowerStack 255CS and PowerTitan 2.0 | Jan 22, 2026
|
|
Einride and IonQ Partnership Uses Quantum Computing to Optimize the Logistics of Electric and Autonomous Freight | Jan 22, 2026
|
|
RS now offers Phoenix Contact's pioneering new NearFi technology | Jan 22, 2026
|
|
SCAILIUM Debuts "AI Production Layer" to Overcome GPU Starvation and Slash AI Energy Waste | Jan 22, 2026
|
|
MetaOptics to Showcase Five Breakthrough Metalens-Powered Products at CES 2026 | Jan 22, 2026
|
|
No Assembly Required: Barrett Distribution Centers Powers Maxwood Furniture's West Coast DTC Expansion | Jan 22, 2026
|
|
Quantum Art Raises $100 Million in Series A Round to Drive Scalable, Multi-Core Quantum Computing | Jan 22, 2026
|
|
TESSAN to Redefine Global Mobility at CES 2026 with '100 Travelers' Initiative and Flagship Voyager 205 | Jan 22, 2026
|
|
Hesai Recognized as the Only Lidar Company on Morgan Stanley's "Humanoid Tech 25" of Global Robotics Leaders | Jan 22, 2026
|
|
1inch Named Exclusive Swap Provider at Launch for Ledger Multisig | Jan 22, 2026
|
|
|
